Status:
COMPLETED
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Studying the dendritic cells in samples of blood from patients with cancer receiving aflibercept may help doctors learn about the effect of aflibercept on dendritic cells. PURPOSE: This la...
Detailed Description
OBJECTIVES: * Evaluate the effect of in vivo aflibercept on the presence of different populations of dendritic cells (DC) and immature cells (ImC) in the peripheral blood of cancer patients by charac...
Eligibility Criteria
Inclusion
- Diagnosis of advanced solid tumor or non-Hodgkin lymphoma and enrolled on clinical trial VGFT-ST-0202
- Hemoglobin ≥ 10 g/dL
- Willing to undergo phlebotomy
Exclusion
- none listed
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00896662
Start Date
January 1 2005
End Date
August 1 2008
Last Update
April 25 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.